- Home
- Software Solutions
- Resources
- Corporate
AEterna Zentaris
AEterna Zentaris Clinical Studies by Phase of Development
Active Clinical Trials 
| Status | Indication | Name(s) | Phase | Trial Name | Identification |
|---|---|---|---|---|---|
| Active | Adult Growth Hormone Deficiency (AGDH) | >macimorelin, AEZS-130 (formely ADR-07) | Phase_II Phase_III | Investigation of a New, O... | NCT00448747 |
| Active | Ovarian Cancer Endometrial Cancer | >AEZS-108 | Phase_II | Antitumoral Activity and ... | NCT00569257 |
| Active | Benign Prostatic Hypertrophy | >cetrorelix >cetrorelix >placebo | Phase_III | Cetrorelix Pamoate in Pat... | NCT00663858 |
| Active | Kala Azar | >initially 2.5 mg/kg/day for 28 days | Phase_I Phase_II | Miltefosine for Brazilian... | NCT00378495 |
| Active | Urothelial Carcinoma | >AEZS-108 >AEZS-108 at MTD | Phase_I Phase_II | A Phase I/II Trial of AEZ... | NCT01234519 |
| Active | Prostate Cancer Hormone-resistant Prostate Cancer Recurrent Prostate Cancer Stage IV Prostate Cancer | >laboratory biomarker analysis >questionnaire administration >doxorubicin-GnRH agonist conjugate AEZS-108 | Phase_I Phase_II | Doxorubicin-GnRH Agonist ... | NCT01240629 |
Completed Clinical Trials
| Status | Indication | Name(s) | Phase | Trial Name | Identification |
|---|---|---|---|---|---|
| Completed | Benign Prostatic Hyperplasia (BPH) | >Cetrorelix Pamoate | Phase_III | Cetrorelix Pamoate IM Reg... | NCT00670306 |
| Completed | Premenopause | >Cetrorelix | Clinical Pharmacological ... | NCT00628121 | |
| Terminated | Benign Prostatic Hypertrophy | >Cetrorelix 52 mg week 0, 26, 52 and 78, 26 mg week 2, 28, 54 and 80 >Cetrorelix-Placebo >Placebo-Cetrorelix | Phase_III | Cetrorelix Pamoate Regime... | NCT00449150 |
| Completed | Multiple Myeloma and Plasma Cell Neoplasm | >shark cartilage extract AE-941 | Phase_II | AE-941 in Treating Patien... | NCT00022282 |
| Completed | Kidney Cancer | >shark cartilage extract AE-941 | Phase_III | AE-941 in Treating Patien... | NCT00005995 |